Minerva Neurosciences (NERV) Retained Earnings (2013 - 2026)
Minerva Neurosciences posted quarterly Retained Earnings of -$814.2 million for Q1 2026, down 103.99% year-on-year from $20.4 billion in Q1 2025, and down 18.21% on a QoQ basis from -$688.8 million in Q4 2025.
Minerva Neurosciences (NERV) has 14 years of Retained Earnings data on file, last reported at -$814.2 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 103.99% year-over-year to -$814.2 million; the trailing twelve-month figure through Mar 2026 stood at -$814.2 million (down 103.99% YoY), and the FY2025 full-year result was -$688.8 million, down 74.21% from the prior year.
- Retained Earnings for Q1 2026 stood at -$814.2 million, down from -$688.8 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$344.5 million in Q1 2022 and bottomed at -$814.2 million in Q1 2026.
- The 5-year median for Retained Earnings is -$395.4 million (2024), against an average of -$428.1 million.
- The widest annual swing landed in 2025, when Retained Earnings climbed 2.71%; it then plunged 103.99% in 2026.
- A 5-year view of Retained Earnings shows it stood at -$366.8 million in 2022, then retreated by 8.18% to -$396.8 million in 2023, then rose by 0.36% to -$395.4 million in 2024, then tumbled by 74.21% to -$688.8 million in 2025, then declined by 18.21% to -$814.2 million in 2026.
- The last three Retained Earnings figures came in at -$814.2 million (Q1 2026), -$688.8 million (Q4 2025), and -$405.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - | -814.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -814.20 Mn |
| Dec 31, 2025 | -688.80 Mn |
| Sep 30, 2025 | -405.13 Mn |
| Jun 30, 2025 | -402.40 Mn |
| Mar 31, 2025 | -399.13 Mn |
| Dec 31, 2024 | -395.38 Mn |
| Sep 30, 2024 | -391.10 Mn |
| Jun 30, 2024 | -413.62 Mn |
| Mar 31, 2024 | -405.38 Mn |
| Dec 31, 2023 | -396.82 Mn |
| Sep 30, 2023 | -387.80 Mn |
| Jun 30, 2023 | -379.97 Mn |
| Mar 31, 2023 | -373.78 Mn |
| Dec 31, 2022 | -366.81 Mn |
| Sep 30, 2022 | -360.10 Mn |
| Jun 30, 2022 | -353.18 Mn |
| Mar 31, 2022 | -344.47 Mn |
| Dec 31, 2021 | -334.70 Mn |
| Sep 30, 2021 | -313.40 Mn |
| Jun 30, 2021 | -304.19 Mn |
| Mar 31, 2021 | -344.50 Mn |
| Dec 31, 2020 | -284.80 Mn |
| Sep 30, 2020 | -277.50 Mn |
| Jun 30, 2020 | -304.20 Mn |
| Mar 31, 2020 | -298.89 Mn |
| Dec 31, 2019 | -286.74 Mn |
| Sep 30, 2019 | -256.82 Mn |
| Jun 30, 2019 | -242.86 Mn |
| Mar 31, 2019 | -230.38 Mn |
| Dec 31, 2018 | -214.55 Mn |
| Sep 30, 2018 | -201.35 Mn |
| Jun 30, 2018 | -189.33 Mn |
| Mar 31, 2018 | -176.80 Mn |
| Dec 31, 2017 | -164.38 Mn |
| Sep 30, 2017 | -164.54 Mn |
| Jun 30, 2017 | -153.28 Mn |
| Mar 31, 2017 | -143.50 Mn |
| Dec 31, 2016 | -132.86 Mn |
| Sep 30, 2016 | -123.45 Mn |
| Jun 30, 2016 | -115.03 Mn |
| Mar 31, 2016 | -109.82 Mn |
| Dec 31, 2015 | -101.81 Mn |
| Sep 30, 2015 | -93.37 Mn |
| Jun 30, 2015 | -87.43 Mn |
| Mar 31, 2015 | -80.82 Mn |
| Dec 31, 2014 | -74.73 Mn |
| Sep 30, 2014 | -67.29 Mn |
| Jun 30, 2014 | -40.13 Mn |
| Dec 31, 2013 | -17.83 Mn |